FDA Approves New Drug for Postpartum Depression,
March 22, 2019

One in nine women in the United States experience symptoms of postpartum depression, a terrifying illness that is often difficult to treat.

That’s why we’re excited by news that the FDA has approved Brexanolone, a drug over 40 years in the making that is the first ever to specifically target the condition. The approval of Brexanolone is a cause for celebration for the entire field of neuroscience.

Click here to read the full article…